Next Science Limited Stock

Equities

NXS

AU0000041329

Pharmaceuticals

Market Closed - Australian S.E. 02:10:44 2024-04-26 EDT 5-day change 1st Jan Change
0.34 AUD +7.94% Intraday chart for Next Science Limited -21.84% 0.00%

Financials

Sales 2024 * 32.71M 50.07M 44.71M Sales 2025 * 40.67M 62.26M 55.59M Capitalization 64.68M 99.02M 88.41M
Net income 2024 * -13M -19.9M -17.77M Net income 2025 * -8M -12.25M -10.94M EV / Sales 2024 * 1.59 x
Net cash position 2024 * 12.75M 19.52M 17.43M Net cash position 2025 * 5.02M 7.68M 6.86M EV / Sales 2025 * 1.47 x
P/E ratio 2024 *
-4.54 x
P/E ratio 2025 *
-10.8 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.94%
1 week-21.84%
Current month+4.62%
1 month-5.56%
3 months-1.45%
6 months+54.55%
More quotes
1 week
0.31
Extreme 0.31
0.43
1 month
0.31
Extreme 0.31
0.50
Current year
0.29
Extreme 0.285
0.50
1 year
0.18
Extreme 0.18
0.75
3 years
0.18
Extreme 0.18
1.98
5 years
0.18
Extreme 0.18
4.73
10 years
0.18
Extreme 0.18
4.73
More quotes
Managers TitleAgeSince
Founder - 17-10-19
Chief Executive Officer - 23-07-09
Director of Finance/CFO - 23-05-25
Members of the board TitleAgeSince
Chief Executive Officer - 23-07-09
Director/Board Member - 23-08-22
Director/Board Member - 17-05-31
More insiders
Date Price Change Volume
24-04-26 0.34 +7.94% 201,976
24-04-24 0.315 -25.00% 877,171
24-04-23 0.42 -1.18% 195,607
24-04-22 0.425 -2.30% 116,519
24-04-19 0.435 -7.45% 383,845

Delayed Quote Australian S.E., April 26, 2024 at 02:10 am

More quotes
Next Science Limited is an Australia-based medical technology company. The Company’s primary focus is on the development and commercialization of its proprietary XBIO technology to reduce the impact of biofilm-based infections on human health. XBIO is a non-toxic technology with an efficacy in eradicating both biofilm-based and free-floating bacteria. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. BLASTX Antimicrobial Wound Gel provides wound management by maintaining a moist wound environment, which is conducive to wound healing.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.2217 USD
Average target price
0.2415 USD
Spread / Average Target
+8.92%
Consensus

Quarterly revenue - Rate of surprise